All Search Results
News Releases
Feb 11, 2026, 17:31 ET EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
September 2025, Firmonertinib showed a 68.2% ORR and 16 months mPFS in EGFR PACC-mutant NSCLC (Phase Ib FURTHER trial). It also demonstrated strong CNS activity, including complete responses in brain metastases.In September 2025, Sunvozertinib achieved an ORR >80% and 100% disease
More news about: DelveInsight Business Research, LLP
Feb 11, 2026, 16:01 ET Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
a landmark narrative review on FDA-approved vesicular monoamine transporter 2 (VMAT2) inhibitors demonstrating the unique profile of INGREZZA in CNS Spectrums. The review highlighted the distinct profile of INGREZZA, including selective VMAT2 targeting, simplified dosing without required titration
More news about: Neurocrine Biosciences, Inc.
Feb 10, 2026, 10:00 ET SkyGrid and Port San Antonio Partner to Enable Advanced Air Mobility at a Joint-Use Airfield
awareness Advanced Air Mobility service provisions Airport and vertiport operational concepts Communication, navigation, and surveillance (CNS) systems and cyber-resilient infrastructure Ground system certification and operational approvals The collaboration will also explore
More news about: SkyGrid
Feb 10, 2026, 08:30 ET Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
looking to refresh aging CNS pipelines. A single successful NSA platform can support multiple indications, creating built-in expansion opportunities and upside optionality. As mental health remains a top global healthcare priority and capital continues flowing into differentiated CNS assets, NSAs are increasingly
More news about: Market News Updates
Feb 10, 2026, 08:00 ET Cumulus Neuroscience Enters Japanese Market to Advance Novel Cognitive Biomarkers with New Customer Shionogi & Co., Ltd.
products in several therapeutic areas including anti-infectives, pain, CNS disorders, cardiovascular diseases and gastroenterology. Shionogi's research and development currently target two therapeutic areas: infectious diseases and pain/CNS disorders. For more information on Shionogi & Co., Ltd., please
More news about: Cumulus Neuroscience
